Literature DB >> 11168635

Functional activity of CD40 antibodies correlates to the position of binding relative to CD154.

T A Barr1, A W Heath.   

Abstract

In this study we describe the characterization of a panel of 12 anti-mouse CD40 monoclonal antibodies (mAb). Characterization was performed in terms of antibody-binding site relative to the CD154 ligand, and the relationship between position and functional outcome of binding. The antibodies divided into three groups. The first were strong inhibitors of CD154 binding, and induced strong proliferative and activation signals to B cells. Two antibodies gave intermediary inhibition and comparable levels of activation. The remaining antibodies were found to bind outside the CD154 binding site and were poor inducers of B-cell activation. Data presented show a strong correlation between location of mAb binding and the resultant activation signal delivered. This correlation is shown to be independent of the isotype of the antibody involved and of its affinity. Implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168635      PMCID: PMC1783151          DOI: 10.1046/j.1365-2567.2001.01148.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Monoclonal antibodies to murine CD40 define two distinct functional epitopes.

Authors:  A W Heath; W W Wu; M C Howard
Journal:  Eur J Immunol       Date:  1994-08       Impact factor: 5.532

2.  Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.

Authors:  E A Clark; J A Ledbetter
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

3.  Activation of human B lymphocytes through CD40 and interleukin 4.

Authors:  A Vallé; C E Zuber; T Defrance; O Djossou; M De Rie; J Banchereau
Journal:  Eur J Immunol       Date:  1989-08       Impact factor: 5.532

4.  Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells.

Authors:  M Baccam; G A Bishop
Journal:  Eur J Immunol       Date:  1999-12       Impact factor: 5.532

5.  Molecular and biological characterization of a murine ligand for CD40.

Authors:  R J Armitage; W C Fanslow; L Strockbine; T A Sato; K N Clifford; B M Macduff; D M Anderson; S D Gimpel; T Davis-Smith; C R Maliszewski
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

Review 6.  Tumor necrosis factor receptor superfamily members and their ligands.

Authors:  R J Armitage
Journal:  Curr Opin Immunol       Date:  1994-06       Impact factor: 7.486

Review 7.  The CD40 antigen and its ligand.

Authors:  J Banchereau; F Bazan; D Blanchard; F Brière; J P Galizzi; C van Kooten; Y J Liu; F Rousset; S Saeland
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

8.  CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome.

Authors:  R C Allen; R J Armitage; M E Conley; H Rosenblatt; N A Jenkins; N G Copeland; M A Bedell; S Edelhoff; C M Disteche; D K Simoneaux
Journal:  Science       Date:  1993-02-12       Impact factor: 47.728

9.  Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM.

Authors:  U Korthäuer; D Graf; H W Mages; F Brière; M Padayachee; S Malcolm; A G Ugazio; L D Notarangelo; R J Levinsky; R A Kroczek
Journal:  Nature       Date:  1993-02-11       Impact factor: 49.962

10.  Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation.

Authors:  P Lane; T Brocker; S Hubele; E Padovan; A Lanzavecchia; F McConnell
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  15 in total

1.  A potent adjuvant effect of CD40 antibody attached to antigen.

Authors:  Tom A Barr; Adele L McCormick; Jennifer Carlring; Andrew W Heath
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

2.  Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library.

Authors:  Peter Ellmark; Camilla Ottosson; Carl A K Borrebaeck; Ann-Christin Malmborg Hager; Christina Furebring
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

3.  Differential responses of human B-lymphocyte subpopulations to graded levels of CD40-CD154 interaction.

Authors:  Sonia Néron; Claudia Racine; Annie Roy; Matthieu Guérin
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

Review 4.  Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Authors:  Raul Elgueta; Micah J Benson; Victor C de Vries; Anna Wasiuk; Yanxia Guo; Randolph J Noelle
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

5.  CD40 and tumour necrosis factor-α co-operate to up-regulate inducuble nitric oxide synthase expression in macrophages.

Authors:  Jose-Andres C Portillo; Luis Muniz Feliciano; Genevieve Okenka; Frederick Heinzel; M Cecilia Subauste; Carlos S Subauste
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

6.  Pre-assembly of the extracellular domains of CD40 is not necessary for rescue of mouse B cells from anti-immunoglobulin M-induced apoptosis.

Authors:  Peter Ellmark; Christina Furebring; Carl A K Borrebaeck
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

7.  Anti-CD40 antibody 2C10 binds to a conformational epitope at the CD40-CD154 interface that is conserved among primate species.

Authors:  Anthony J Michaels; Matteo Stoppato; Walter J Flores; Keith A Reimann; Kathleen D Engelman
Journal:  Am J Transplant       Date:  2019-09-12       Impact factor: 8.086

8.  CD40mAb adjuvant induces a rapid antibody response that may be beneficial in post-exposure prophylaxis.

Authors:  Vijay Ns Bhagawati-Prasad; Evy De Leenheer; Nadine P Keefe; Lorna A Ryan; Jennifer Carlring; Andrew W Heath
Journal:  J Immune Based Ther Vaccines       Date:  2010-02-04

9.  APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application.

Authors:  Erin L Filbert; Pia K Björck; Minu K Srivastava; Frances R Bahjat; Xiaodong Yang
Journal:  Cancer Immunol Immunother       Date:  2021-01-03       Impact factor: 6.968

10.  A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.

Authors:  Sarah A Weiss; Dijana Djureinovic; Shlomit Jessel; Irina Krykbaeva; Lin Zhang; Lucia Jilaveanu; Amanda Ralabate; Barbara Johnson; Neta Shanwetter Levit; Gail Anderson; Daniel Zelterman; Wei Wei; Amit Mahajan; Ovid Trifan; Marcus Bosenberg; Susan M Kaech; Curtis J Perry; William Damsky; Scott Gettinger; Mario Sznol; Michael Hurwitz; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2021-06-17       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.